Processing

Please wait...

Settings

Settings

Goto Application

1. WO2019050362 - ANTIBODY AGAINST HUMAN DLK1 AND USE THEREOF

Publication Number WO/2019/050362
Publication Date 14.03.2019
International Application No. PCT/KR2018/010559
International Filing Date 10.09.2018
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 14/725 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
A61K 47/68 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C12N 5/0783 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
CPC
A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 14/7051
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70503Immunoglobulin superfamily
7051T-cell receptor (TcR)-CD3 complex
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 2317/565
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
565Complementarity determining region [CDR]
C07K 2317/567
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
567Framework region [FR]
C07K 2317/622
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
60characterized by non-natural combinations of immunoglobulin fragments
62comprising only variable region components
622Single chain antibody (scFv)
Applicants
  • 주식회사 와이바이오로직스 Y-BIOLOGICS INC. [KR]/[KR]
Inventors
  • 임정채 LIM, Jung Chae
  • 신지영 SHIN, Ji-Young
  • 윤선하 YOON, Sunha
  • 이상필 LEE, Sang Pil
  • 최윤선 CHOI, Yunseon
  • 이지수 LEE, Jisu
  • 조영규 CHO, Young-Gyu
  • 유석호 YOO, Seok Ho
  • 김응철 KIM, Yeung chul
  • 이시형 LEE, Si Hyung
  • 박재은 PARK, Jae Eun
  • 송영자 SONG, Youngja
  • 백기선 BAEK, Gi Sun
  • 박범찬 PARK, Bum-chan
  • 박영우 PARK, Young Woo
Agents
  • 이처영 LEE, Cheo Young
  • 장제환 CHANG, Je Hwan
Priority Data
10-2017-011526308.09.2017KR
Publication Language Korean (KO)
Filing Language Korean (KO)
Designated States
Title
(EN) ANTIBODY AGAINST HUMAN DLK1 AND USE THEREOF
(FR) ANTICORPS DIRIGÉ CONTRE DLK1 HUMAIN ET UTILISATION ASSOCIÉE
(KO) 인간 DLK1에 대한 항체 및 이의 용도
Abstract
(EN)
The present invention relates to an antibody against delta-like 1 homolog (Drosophila) (DLK1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, an antibody drug conjugate (ADC) comprising the same, a pharmaceutical composition for treating cancer, a composition for diagnosing cancer, and a chimeric antigen receptor (CAR) and a T-cell engager comprising the same.
(FR)
La présente invention concerne un anticorps contre DLK1 (delta-like 1 homolog (Drosophila) ou un fragment de liaison à l'antigène de celui-ci, un acide nucléique codant pour celui-ci, un vecteur comprenant l'acide nucléique, une cellule transformée avec le vecteur, un procédé de production de l'anticorps ou d'un fragment de liaison à l'antigène de celui-ci, un conjugué anticorps-médicament (ADC) comprenant celui-ci, une composition pharmaceutique pour le traitement du cancer, une composition pour le diagnostic du cancer, et un récepteur d'antigène chimère (CAR) et un anticorps engageant les lymphocytes T le comprenant.
(KO)
본 발명은 DLK1(delta-like 1 homolog (Drosophila))에 대한 항체 또는 이의 항원 결합 단편, 이를 코딩하는 핵산, 상기 핵산을 포함하는 벡터, 상기 벡터로 형질전환된 세포, 상기 항체 또는 그의 항원 결합 단편의 제조방법, 이를 포함하는 항체-약물 접합체(Antibody drug conjugate: ADC), 암 치료용 약학 조성물, 암 진단용 조성물, 이를 포함하는 키메라 항원 수용체(Chimeric antigen receptor: CAR) 및 T 세포 관여자(T-cell engager)에 관한 것이다.
Also published as
JP2020514200
Latest bibliographic data on file with the International Bureau